Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.
Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.
Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.
Ian W. Flinn, MD, PhD, discusses the opportunity for second-line tafasitamab (MOR208, formerly Xmab®5574) as a palliative treatment of patients with diffuse large B-cell lymphoma.
Haifaa Abdulhaq, MD, discusses the safety profile of tafasitamab (MOR208) in diffuse large B-cell lymphoma.
Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.
Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5